Shots:
- CervoMed has completed enrollment in the P-IIa study of neflamapimod for the treatment of nonfluent variant primary progressive aphasia (nfvPPA), a type of frontotemporal dementia, with interim results to be presented at CTAD 2026
- The study will evaluate the safety, PK, & clinical effects of neflamapimod (40mg, PO, TID; n=19 and 80mg, BID; n=6) in 25 pts with nfvPPA for 24wks., followed by a 12wk. PBO-controlled extension
- Neflamapimod is a brain-penetrant selective p38α MAP kinase inhibitor designed to reduce neuroinflammation, restore synaptic function, & slow neurodegenerative disease progression
Ref: Globenewswire | Image: CervoMed | Press Release
Related News: Ionis Completes Patient Enrollment in Cohort 1 of P-III (REVEAL) Study of Obudanersen in Angelman syndrome (AS)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
